Literature DB >> 12450691

The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis.

Mohammad Hossein Alimohammadian1, Ali Khamesipour, Haiedeh Darabi, Alireza Firooz, Shirin Malekzadeh, Ahmad Bahonar, Yahya Dowlati, Farrokh Modabber.   

Abstract

To determine if BCG was required in booster injections for autoclaved Leishmania major (ALM) vaccine, 75 volunteers with no response to leishmanin were injected double-blind and randomly with either ALM+BCG or BCG alone for the first injection and boosted either with ALM+BCG, ALM or BCG alone for the second and third. Addition of BCG to the boosters significantly increased the frequency and the magnitude of leishmanin skin tests (LSTs); however, there was no difference in proliferative and IFN-gamma responses (a month and a year later). Three injections of BCG produced no observable adverse reaction; hence BCG could be used in booster injections to increase the protective potential of this candidate vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450691     DOI: 10.1016/s0264-410x(02)00458-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Karla de Melo Lima; Célio Lopes Silva; José Maciel Rodrigues; Ana Paula Fernandes
Journal:  Parasitol Res       Date:  2006-01-24       Impact factor: 2.289

2.  Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.

Authors:  Mohsen Tafaghodi; Ali Khamesipour; Mahmoud R Jaafari
Journal:  Parasitol Res       Date:  2010-12-02       Impact factor: 2.289

3.  Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response.

Authors:  S Farajnia; F Mahboudi; S Ajdari; N E Reiner; A Kariminia; M H Alimohammadian
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 4.  Leishmania vaccine development: exploiting the host-vector-parasite interface.

Authors:  S G Reed; R N Coler; D Mondal; S Kamhawi; J G Valenzuela
Journal:  Expert Rev Vaccines       Date:  2015-11-23       Impact factor: 5.217

5.  Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis.

Authors:  Hosein Keshavarz Valian; Lavinia Khoshabe Abdollah Kenedy; Mahmoud Nateghi Rostami; Akram Miramin Mohammadi; Ali Khamesipour
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

6.  Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins.

Authors:  Mohsen Tafaghodi; Maryam Eskandari; Ali Khamesipour; Mahmoud Reza Jaafari
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

Review 7.  A Historic Review of the Role of CD4+ T-Cell Subsets in Development of the Immune Responses against Cutaneous and Visceral Leishmaniases

Authors:  Mohammad Hossein Alimohmmadian; Soheila Ajdary; Fariborz Bahrami
Journal:  Iran Biomed J       Date:  2022-03-01

8.  Immunity Against Leishmania major Infection: Parasite-Specific Granzyme B Induction as a Correlate of Protection.

Authors:  Thouraya Boussoffara; Sadok Chelif; Melika Ben Ahmed; Mourad Mokni; Afif Ben Salah; Koussay Dellagi; Hechmi Louzir
Journal:  Front Cell Infect Microbiol       Date:  2018-11-13       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.